Eli Lilly Stock (LLY) Outlook for Monday: Latest Deal Headlines, GLP-1 Pill Race, and Wall Street Targets

Eli Lilly and Company heads into the final trading stretch of 2025 with its stock near record territory and investors laser-focused on three forces that can move the shares quickly: the accelerating battle for obesity and diabetes drug dominance, the policy and pricing machinery starting to reshape access to GLP‑1 treatments, and Lilly’s pipeline and business-development cadence beyond today’s blockbusters.

NYSE:LLY · Pharmaceuticals · Stock Market
Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly and Company stock is in the spotlight on December 24, 2025 as investors digest a new round of GLP‑1 headlines that span regulatory momentum, global market expansion, and shifting coverage expectations—all of which feed directly into the long-term demand outlook for Lilly’s obesity and diabetes franchise.
24 December 2025
···
Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

December 23, 2025 — Eli Lilly and Company stock is holding near record territory as investors digest a fresh twist in the weight-loss drug race: the FDA has cleared Novo Nordisk’s first oral version of Wegovy, intensifying competition right as Lilly pushes its own once-daily pill candidate, orforglipron, toward a potential 2026 approval.
23 December 2025
···
Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

December 23, 2025 — Eli Lilly and Company is trading around $1,076 as investors digest a fresh competitive jolt in the obesity-drug race: the FDA has approved Novo Nordisk’s first daily oral version of Wegovy. The headline is about Novo, but the market’s real question is about Lilly’s moat: can LLY keep dominating the category while a new “pill era” starts to form? Reuters+1
23 December 2025
··
Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk A/S is back in the market’s spotlight on 23 December 2025 after a major regulatory milestone: the U.S. Food and Drug Administration approved a pill version of Wegovy, making it the first oral GLP‑1 receptor agonist cleared for chronic weight management in the U.S. The news sent Novo Nordisk shares sharply higher in early trading and reverberated across European markets, where the company’s move helped lift healthcare stocks. Novo Nordisk+2Reuters+2
23 December 2025
···
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

December 22, 2025 — ABIVAX Société Anonyme is back in the spotlight today, with traders juggling two storylines that can move a biotech stock fast: renewed takeover speculation involving Eli Lilly and Abivax’s addition to the Nasdaq Biotechnology Index, effective before today’s market open. GlobeNewswire+2Investing.com+2
22 December 2025
····
Eli Lilly (LLY) Stock: What to Know Before the U.S. Market Opens on Dec. 22, 2025

Eli Lilly (LLY) Stock: What to Know Before the U.S. Market Opens on Dec. 22, 2025

Eli Lilly and Company enters the final full holiday trading week of 2025 with momentum—and with headlines that can move the stock quickly in thin year‑end liquidity. The most important story remains Lilly’s dominance in obesity and diabetes medicines, but investors are now pricing in what comes next: oral GLP‑1 candidates, next‑generation “triple agonist” retatrutide, and a shifting U.S. policy backdrop that’s pushing drugmakers toward direct-to-consumer pricing and discount channels.
22 December 2025
··
Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

As of Sunday, December 21, 2025, Eli Lilly and Company heads into a holiday-shortened trading week near recent highs, after a busy stretch of headlines spanning next-generation obesity drugs, potentially accelerated FDA review timelines, price cuts aimed at widening access, and a fast-evolving U.S. drug-pricing agenda.
21 December 2025
··
Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Dec. 20, 2025 — Eli Lilly and Company is closing out 2025 with momentum—and with fresh headlines that underscore why Eli Lilly stock has become one of the market’s most closely watched healthcare names. Shares last closed at $1,071.44 after trading between $1,059.01 and $1,075.38, keeping the stock within reach of its recent highs. Stock Analysis
20 December 2025
···
Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly and Company finished Thursday’s session higher and held those gains in after-hours trading, as investors digested fresh late-stage data for its oral obesity candidate orforglipron—and weighed a second, potentially market-moving theme: pricing pressure and affordability initiatives.
18 December 2025
···
1 … 7 8 9 10 11 … 14
Follow on Google News
Add as preferred source Open in Google News